Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahe

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight an

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight an

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperfor

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lower

Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-y

Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-T

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and l

Analysts change outlook on top names: Truist cut KFY price target, Oppenheimer raised AZO target, B.

Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overwei

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and r

Deutsche Bank analyst David Hoang maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and ra

HC Wainwright & Co. analyst Douglas Tsao maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a

Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated

US stocks fell, Nasdaq down 1%, Dow down 1.71%, S&P 500 down 1.43%. Energy shares down 0.1%, con

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raise

Baird analyst Brian Skorney maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and r

Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong sei

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

US stocks fall as Dow Jones drops over 1% on Monday, while NASDAQ and S&P 500 also decline. Korn

Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner,

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raise

Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overwei

Wolfe Research analyst Rudy Li initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a O

Biohaven's Phase 2 study with BHV-7000 in MDD did not meet its primary endpoint of reducing depr

Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overwei

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OL

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicate

JP Morgan analyst Tessa Romero maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight an

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperfor

Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overwei

Needham analyst Serge Belanger reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and main

Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.15) per share which met the ana

VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.

Chardan Capital analyst Rudy Li maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and main

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earni

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn